Overview

Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants

Status:
Terminated
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
This study investigated whether fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy, was safe and effective in treating participants with PKAN.
Phase:
Phase 3
Details
Lead Sponsor:
Retrophin, Inc.
Travere Therapeutics, Inc.